United States Healthcare Equipment & Supplies

Renalytix PLC (RENX)

Track

Track

Renalytix PLC experienced three recent transactions, including two small purchases by CEO James McCullough and a significant sale by Non-Executive Chairman Christopher Mills. Despite a 160.9% stock price increase over ninety days, overall insider activity remains mixed. No further earnings report details are currently available for this healthcare firm.
Ticker: RENX Exchange: LSE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Renalytix PLC. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.4
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Sale
Price
111.61
Quantity 46,422
Value £4,394,202
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
300.83
Quantity 72,087
Value US$1,772,756
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
246.56
Quantity 30,172
Value US$2,111,554
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
3.15
Quantity 750
Value US$2,362
Joel Jung interim Chief Financial Officer Officer
Transaction date
Purchase
Price
2.85
Quantity 500
Value US$1,425
Joel Jung interim Chief Financial Officer Officer
Transaction date
Purchase
Price
2.90
Quantity 2,000
Value US$5,800
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
3.01
Quantity 3,010
Value US$9,072
Fergus Fleming Chief Technology Officer & Executive Director Executive Director
Transaction date
Purchase
Price
0.10
Quantity 25,000
Value £2,438
3.2
Julain Baines Executive Chairman Director
Transaction date
Purchase
Price
0.09
Quantity 23,000
Value £1,955
Howard Doran President of Renalytix
Transaction date
Purchase
Price
0.09
Quantity 50,000
Value £4,450
3.3
James McCullough CEO Officer
Transaction date
Purchase
Price
0.09
Quantity 25,000
Value £2,125
Howard Doran President
Transaction date
Purchase
Price
0.08
Quantity 50,000
Value £4,000
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Purchase
Price
0.07
Quantity 48,601
Value £3,402
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
0.08
Quantity 53,300
Value £3,998
3.2
Julian Baines Executive Chairman Director
Transaction date
Purchase
Price
0.07
Quantity 23,989
Value £1,739
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Purchase
Price
0.09
Quantity 500,000
Value £45,000
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Sale
Price
0.08
Quantity 83,696
Value £6,696
Christopher Mills Non-Executive Chairman Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Purchase
Price
0.90
Quantity 346,375
Value £311,738
Christopher Mills Chief Executive Officer Executive Director
Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person
Transaction date
Sale
Price
11.25
Quantity 6,100
Value £68,625
Fergus Fleming Chief Technology Officer Officer
Transaction date
Sale
Price
10.75
Quantity 15,000
Value £161,250
Christopher Mills non-exec director and Interim Chair Executive Director
Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person
Transaction date
Sale
Price
11.35
Quantity 17,000
Value £193,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-01 2026-09-29 S Sale
2.4
Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
46,422
111.61
£4,394,202 		46,422 111.61 £4,394,202
2026-09-16 2026-09-15 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
72,087
300.83
US$1,772,756 		72,087 300.83 US$1,772,756
2026-09-11 2026-09-09 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
30,172
246.56
US$2,111,554 		30,172 246.56 US$2,111,554
2026-02-13 2026-02-12 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
750
3.15
US$2,362 		750 3.15 US$2,362
2026-02-13 2026-02-11 B Purchase
Joel Jung

interim Chief Financial Officer

Officer
500
2.85
US$1,425 		500 2.85 US$1,425
2026-02-12 2026-02-11 B Purchase
Joel Jung

interim Chief Financial Officer

Officer
2,000
2.90
US$5,800 		2,000 2.90 US$5,800
2026-02-12 2026-02-11 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
3,010
3.01
US$9,072 		3,010 3.01 US$9,072
2024-12-20 2024-12-20 B Purchase Fergus Fleming

Chief Technology Officer & Executive Director

Executive Director
25,000
0.10
£2,438 		25,000 0.10 £2,438
2024-12-11 2024-12-10 B Purchase
3.2
Julain Baines

Executive Chairman

Director
23,000
0.09
£1,955 		23,000 0.09 £1,955
2024-12-11 2024-12-10 B Purchase Howard Doran

President of Renalytix
50,000
0.09
£4,450 		50,000 0.09 £4,450
2024-12-11 2024-12-10 B Purchase
3.3
James McCullough

CEO

Officer
25,000
0.09
£2,125 		25,000 0.09 £2,125
2024-12-09 2024-12-09 B Purchase Howard Doran

President
50,000
0.08
£4,000 		50,000 0.08 £4,000
2024-12-11 2024-12-05 B Purchase Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
48,601
0.07
£3,402 		48,601 0.07 £3,402
2024-12-06 2024-12-05 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
53,300
0.08
£3,998 		53,300 0.08 £3,998
2024-12-04 2024-12-04 B Purchase
3.2
Julian Baines

Executive Chairman

Director
23,989
0.07
£1,739 		23,989 0.07 £1,739
2024-10-11 2024-10-08 B Purchase Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
500,000
0.09
£45,000 		500,000 0.09 £45,000
2024-10-11 2024-10-07 S Sale Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
83,696
0.08
£6,696 		83,696 0.08 £6,696
2023-02-10 2023-02-08 B Purchase Christopher Mills

Non-Executive Chairman

Through Harwood Capital LLP, a closely affiliated person Executive Director
346,375
0.90
£311,738 		346,375 0.90 £311,738
2021-06-28 2021-06-25 S Sale Christopher Mills

Chief Executive Officer

Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person Executive Director
6,100
11.25
£68,625 		6,100 11.25 £68,625
2021-06-25 2021-06-25 S Sale Fergus Fleming

Chief Technology Officer

Officer
15,000
10.75
£161,250 		15,000 10.75 £161,250
2021-06-22 2021-06-18 S Sale Christopher Mills

non-exec director and Interim Chair

Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person Executive Director
17,000
11.35
£193,000 		17,000 11.35 £193,000
Explore more

More insider trading research around Renalytix PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America